Autolus Therapeutics plc

Contributing Author

Recent Articles by Autolus Therapeutics plc

Nov-13	Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London AUTL -5.88% GlobeNewswire
Nov-12	Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates AUTL GlobeNewswire
Nov-03	Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025 AUTL GlobeNewswire
Oct-30	Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 AUTL GlobeNewswire
Oct-27	Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025 AUTL GlobeNewswire
Oct-20	Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis AUTL GlobeNewswire
Oct-15	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUTL GlobeNewswire
Sep-16	Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025 AUTL GlobeNewswire
Aug-12	Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates AUTL GlobeNewswire
Jul-24	Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 AUTL GlobeNewswire
Jul-21	Autolus Therapeutics' CAR T Therapy AUCATZYL (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) AUTL GlobeNewswire
Jul-15	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUTL GlobeNewswire
Jun-12	Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress AUTL GlobeNewswire
May-29	Autolus Therapeutics to Participate in Upcoming Investor Conferences AUTL GlobeNewswire
May-23	Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) AUTL GlobeNewswire
May-14	Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress AUTL GlobeNewswire
May-08	Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates AUTL GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.